Clinical considerations on posaconazole administration and therapeutic drug monitoring in allogeneic hematopoietic cell transplant recipients
| Autor: | Mateja, Kraljevic, Nina, Khanna, Michael, Medinger, Jakob, Passweg, Stavroula, Masouridi-Levrat, Yves, Chalandon, Nicolas J, Mueller, Urs, Schanz, Nathalie, Vernaz, Christian, Van Delden, Dionysios, Neofytos, Yerly, Patrick |
|---|---|
| Přispěvatelé: | Gasche-Soccal, Paola Marina Alessandra, Gaudet-Blavignac, Christophe, Martin, Pierre-Yves, Posfay Barbe, Klara, Simonetta, Federico, Toso, Christian, Villard, Jean, University of Zurich |
| Rok vydání: | 2020 |
| Předmět: |
Allogeneic hematopoietic cell transplant recipients
Adult Male Posaconazole medicine.medical_specialty Adolescent 610 Medicine & health Therapeutic drug monitoring Gastroenterology 10234 Clinic for Infectious Diseases Young Adult 03 medical and health sciences 0302 clinical medicine Interquartile range Internal medicine medicine Humans Antifungal treatment Prospective Studies 030212 general & internal medicine Dosing Aged Retrospective Studies ddc:616 0303 health sciences medicine.diagnostic_test Hematopoietic cell 030306 microbiology business.industry Incidence (epidemiology) Hematopoietic Stem Cell Transplantation General Medicine Middle Aged Triazoles Transplant Recipients Treatment Outcome Infectious Diseases 10032 Clinic for Oncology and Hematology Female Antifungal prophylaxis Drug Monitoring business Liver function tests Cohort study medicine.drug |
| Zdroj: | Medical mycology, Vol. 59, No 7 (2021) pp. 701-711 |
| ISSN: | 1460-2709 1369-3786 |
| Popis: | There is a paucity of data on posaconazole (PCZ) dosing and therapeutic-drug-monitoring (TDM) in allogeneic hematopoietic cell transplant recipients (allogeneic-HCTr). This was a 3-year retrospective multicenter study (January 1, 2016 to December 31, 2018) in adult allogeneic-HCTr who received PCZ (intravenously, IV and/or as delayed-release tablet, DRT) as prophylaxis or treatment for ≥7 consecutive days (D) with at least 1-PCZ-level available using data of the Swiss Transplant Cohort Study. The primary objective was to describe the distribution of PCZ-level and identify predictors of therapeutic PCZ-level and associations between PCZ-dosing and PCZ-level. A total of 288 patients were included: 194 (67.4%) and 94 (32.6%) received PCZ as prophylaxis and treatment, respectively, for a median of 90 days (interquartile range, IQR: 42–188.5). There were 1944 PCZ-level measurements performed, with a median PCZ level of 1.3 mg/L (IQR: 0.8-1.96). PCZ-level was |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|